Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary | With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary R&D efforts toward other pipeline darlings.